BP has the luxury of not furthering any studies with MANF until MANF conclusively shows it can cure in humans. First, no way will any of the BPs want to pay grossly diluted and poorly managed AMBS one red nickle for a drug they bring to market in the form of a royalty (sans partnership). BP will either wait for AMBS to fold and buy the rights for MANF at a fire sale or wait until AMBS proves in their own studies that MANF actually works in vivo. Maybe one BP is nice and will partner up to help fund those trials or they let AMBS struggle to come up witht he millions of dollars itself. Hopefully by then AMBS has a nice cash reserve and can extract stupendous terms and a favorable deal to share their MANF with one or select BPs.

Until then, Gerald needs to start showing he can build shareholder value because so far he hasn't.